Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Guglielmelli

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
International Review of Cell and Molecular Biology|November 10, 2021
The MPL mutationPaola Guglielmelli, Laura Calabresi
Hematology. American Society of Hematology. Education Program|December 9, 2022
Molecular prognostication in Ph-negative MPNs in 2022Alessandro Maria Vannucchi, Paola Guglielmelli
Seminars in Thrombosis and Hemostasis|May 2, 2013
JAK2 mutation-related disease and thrombosisAlessandro M Vannucchi, Paola Guglielmelli
F1000 Medicine Reports|October 16, 2010
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasmsPaola Guglielmelli, Alessandro M Vannucchi
Hematology. American Society of Hematology. Education Program|December 10, 2017
What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?Alessandro M Vannucchi, Paola Guglielmelli
Blood Reviews|June 18, 2020
Current management strategies for polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Alessandro M Vannucchi
Current Opinion in Oncology|September 1, 2010
Advances in understanding and management of polycythemia veraAlessandro M Vannucchi, Paola Guglielmelli
American Journal of Hematology|March 10, 2025
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future PerspectivesGiuseppe G Loscocco, Paola Guglielmelli
American Journal of Hematology|March 14, 2025
Topics of Interest in Women With Myeloproliferative NeoplasmsNatasha Szuber, Paola Guglielmelli, Naseema Gangat
Expert Opinion on Therapeutic Targets|May 6, 2020
Polycythemia vera: the current status of preclinical models and therapeutic targetsNiccolò Bartalucci, Paola Guglielmelli, Alessandro M Vannucchi
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
International Review of Cell and Molecular Biology|November 10, 2021
The MPL mutationPaola Guglielmelli, Laura Calabresi
Hematology. American Society of Hematology. Education Program|December 9, 2022
Molecular prognostication in Ph-negative MPNs in 2022Alessandro Maria Vannucchi, Paola Guglielmelli
Seminars in Thrombosis and Hemostasis|May 2, 2013
JAK2 mutation-related disease and thrombosisAlessandro M Vannucchi, Paola Guglielmelli
F1000 Medicine Reports|October 16, 2010
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasmsPaola Guglielmelli, Alessandro M Vannucchi
Hematology. American Society of Hematology. Education Program|December 10, 2017
What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?Alessandro M Vannucchi, Paola Guglielmelli
Blood Reviews|June 18, 2020
Current management strategies for polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Alessandro M Vannucchi
Current Opinion in Oncology|September 1, 2010
Advances in understanding and management of polycythemia veraAlessandro M Vannucchi, Paola Guglielmelli
American Journal of Hematology|March 10, 2025
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future PerspectivesGiuseppe G Loscocco, Paola Guglielmelli
American Journal of Hematology|March 14, 2025
Topics of Interest in Women With Myeloproliferative NeoplasmsNatasha Szuber, Paola Guglielmelli, Naseema Gangat
Expert Opinion on Therapeutic Targets|May 6, 2020
Polycythemia vera: the current status of preclinical models and therapeutic targetsNiccolò Bartalucci, Paola Guglielmelli, Alessandro M Vannucchi
Pageof 23